Minimal Residual Disease (MRD) Testing
News and reporting on minimal residual disease testing.
Guardant Health, Pfizer Partner to Use Liquid Biopsy to Aid Cancer Therapy Development
Pfizer intends to use Guardant's blood-based tests in global clinical trials, with specific plans to evaluate the clinical utility of its Reveal assay as clinical trial surrogate endpoint.
Invivoscribe's LabPMM Nabs NY State Approval for MRD Assay
The company can now offer the FLT3 ITD MRD Assay in New York state to assess measurable residual disease to guide treatment for acute myeloid leukemia patients.
The company welcomed favorable results last week from a study comparing its test to a narrower ddPCR-based approach in patients from an ongoing interventional trial.
With Positive Multi-Site Trial Data, Elypta Poised for Launch of Kidney Cancer Surveillance Test
Premium
The company presented its results this week at a conference and anticipates that with additional validation early next year, it will be ready to file for regulatory approval.
A discussion at the Precision Medicine Tri-Con demonstrated that stakeholders are narrowing in on the challenges to realizing the promise of solid tumor MRD.